Susquehanna Fundamental Investments LLC Takes Position in Acelyrin, Inc. (NASDAQ:SLRN)

Susquehanna Fundamental Investments LLC bought a new stake in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 160,167 shares of the company's stock, valued at approximately $706,000. Susquehanna Fundamental Investments LLC owned approximately 0.16% of Acelyrin at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Blair William & Co. IL bought a new stake in shares of Acelyrin in the first quarter worth $936,000. Acadian Asset Management LLC acquired a new stake in shares of Acelyrin in the 2nd quarter valued at about $590,000. Jacobs Levy Equity Management Inc. bought a new position in shares of Acelyrin during the first quarter worth about $3,961,000. Los Angeles Capital Management LLC bought a new position in shares of Acelyrin during the second quarter worth about $693,000. Finally, Vanguard Group Inc. grew its stake in Acelyrin by 1.3% in the first quarter. Vanguard Group Inc. now owns 6,237,543 shares of the company's stock worth $42,103,000 after purchasing an additional 81,633 shares in the last quarter. 87.31% of the stock is currently owned by institutional investors and hedge funds.

Acelyrin Stock Down 3.5 %

SLRN stock traded down $0.18 during mid-day trading on Thursday, reaching $4.91. The company had a trading volume of 422,103 shares, compared to its average volume of 1,101,095. Acelyrin, Inc. has a one year low of $3.36 and a one year high of $10.70. The stock has a market capitalization of $490.07 million, a P/E ratio of -2.14 and a beta of 2.34. The stock's 50-day simple moving average is $4.98 and its two-hundred day simple moving average is $5.07.

Acelyrin (NASDAQ:SLRN - Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.78) by ($0.08). During the same quarter in the previous year, the business earned ($0.56) EPS. On average, research analysts forecast that Acelyrin, Inc. will post -3.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on SLRN. HC Wainwright downgraded Acelyrin from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $18.00 to $6.00 in a report on Wednesday, August 14th. Wells Fargo & Company raised shares of Acelyrin from an "equal weight" rating to an "overweight" rating and set a $13.00 price objective for the company in a report on Monday, July 8th. Piper Sandler lowered their target price on shares of Acelyrin from $68.00 to $20.00 and set an "overweight" rating for the company in a research note on Wednesday, August 14th. Finally, Morgan Stanley reduced their price target on shares of Acelyrin from $13.00 to $6.00 and set an "equal weight" rating on the stock in a research report on Monday, August 19th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $10.83.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.